Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management

Area of Science:

• Oncology
• Nephrology
• Endocrinology

Background:

• Hypercalcemia impacts multiple organ systems, with severe cases causing confusion and encephalopathy.
• Malignancy-associated hypercalcemia (MAH) affects 10-30% of cancer patients, indicating a poor prognosis, especially in advanced stages.

Purpose of the Study:

• To review the mechanisms, investigations, and management strategies for malignancy-associated hypercalcemia (MAH).
• To address challenges in dosing antihypercalcemic medications for patients with kidney dysfunction.
• To explore potential targeted therapies for MAH.

Main Methods:

• Comprehensive literature review of MAH mechanisms, diagnostic investigations, and treatment modalities.
• Analysis of existing data on antihypercalcemic agent dosing in patients with reduced glomerular filtration rate.
• Discussion of emerging mechanisms, including immune checkpoint inhibitors and prolonged immobilization.

Main Results:

• MAH is primarily driven by humoral hypercalcemia of malignancy and osteolytic hypercalcemia.
• Novel mechanisms involving cancer medications and immobilization are increasingly recognized.
• Dosing adjustments for antihypercalcemic agents in renal impairment are complex but essential.

Conclusions:

• Effective management of MAH requires understanding its diverse mechanisms and tailoring treatment to hypercalcemia severity.
• Renal function must be considered when prescribing antihypercalcemic agents, necessitating dose adjustments.
• Further research into targeted therapies holds promise for improved MAH management in cancer patients.